Mersacidin is a new peptide antibiotic of the proposed lantibiotic family. It is active in vitro and in vivo against Gram-positive bacteria including the methicillin-resistant Staphylococci. Its in vitro activity is less than those of vancomycin and erythromycin but it shows muchhigher activity in the in vivo system than can be expected from the in vitro testing results. A water soluble potassium salt has been prepared which has an activity profile similar to that of mersacidin, but has better in vivo activity against Streptococcus pyogenes than the parent compound.
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A new peptide antibiotic mersacidin1>2), has been isolated from fermentations of a Bacillus species HIL Y-85,54728. The antibiotic contains the unusual amino acid methyllanthionine, and hence may be grouped in the class termed lantibiotics.
Peptides of this group, besides being antibiotics, have also shown other interesting biological activities. For example, nisin3) has been reported as an antimalarial agent, ancovenin4) as an enzymeinhibitor, Ro 09-01985) as an immunopotentiator and lanthiopeptin6) has been reported to be active against Herpes simplex virus I. Mersacidin is interesting from another perspective; its activity in experimentally infected animals (mice) is significantly higher than would be predicted from its moderate in vitro activity. A similar phenomenonhas been reported concerning the antibiotic spiramycin7) which is less active than erythromycin in the in vitro, but shows much better activity than erythromycin in the in vivo model. In the present communication the antibacterial activities of mersacidin and its water soluble derivative, potassium mersacidin, are reported.
Materials and Methods
In Vitro Antibacterial Activity Mersacidin used in the experiments was isolated and purified in our laboratories, while erythromycin and vancomycin were obtained commercially. The in vitro antibacterial activity of mersacidin was assessed against strains of Staphylococcus including both methicillin-sensitive and methicillin-resistant were used for each of the serial 2-fold dose concentrations of the compounds tested. Treatment was initiated by subcutaneous administration of mersacidin in three doses at 0, 2 and 24hours post infection. ED50 and ED90 are defined as the doses which protected 50 and 90% of the animals, respectively.
Experimental Infections with Methicillin-resistant S. aureus Strains: All experimental conditions were the same as for S. aureus SG 511. The inoculum size for S. aureus E 710 was 2x1010cfu/mouse (1 MLD) , and the inoculum size for S. aureus C 31153 was 2x 109cfu/mouse (1 MLD).
Experimental Infection with S. pyogenes A 77: S. pyogenes A 77 was cultured in ACbroth (Difco) overnight. A log phase culture was prepared and mice were infected intraperitonially.
After 4 hours, the heart blood was asceptically drawn and transferred to crystal violet blood agar mediumand incubated overnight. Typical S. pyogenes colonies were picked up and inoculated in fresh ACbroth. After 5 hours the medium was diluted 1 :2 with 15% sterile skimmed milk and cryopreserved in liquid nitrogen. The cryopreserved culture was used to determine the MLD. Swiss albino mice (18~22g) of either sex received 4 x 103 cfu/0.5ml (1 MLD)by the ip route for chemotherapeutic studies.
Results
Mersacidin inhibits 50% of the methicillin-sensitive S. aureus strains at a concentration of about 5/ig/ml while the corresponding values for vancomycin and erythromycin are around 0.3 /xg/ml and 0.2 /ig/ml, respectively (Fig. 1 ). The same relationship exists when coagulase-negative Staphylococci are Fig. 1 . Antibacterial activity in vitro against Staphylococcus aureus (Strain number=20). à" Erythromycin, A vancomycin, å mersacidin. à"Erythromycin, å² vancomycin, å mersacidin.
considered. Mersacidin inhibits 50% of the strains at a concentration of 16/xg/ml while the corresponding values for vancomycin and erythromycin are 0.5^g/ml and 0.2/zg/ml, respectively (Fig. 2) . However, when MIC90values are considered, mersacidin and erythromycin are approximately equally active. Vancomycin remains the best. Against methicillin-resistant Staphylococci, mersacidin has a somewhat better activity than erythromycin concerning the inhibition of more than 50% of the strains. However vancomycin still maintains its superiority (Fig. 3) . Against quinolone-resistant Staphylococci, vancomycin is again the best (Fig. 4) . Erythromycin is also better than mersacidin against most Staphylococci but to achieve the MIC90the concentrations of erythromycin required are higher than those of mersacidin. Against Enterococci, mersacidin, with MIC values between 16~128^g/ml is much less active than vancomycinwhich inhibits more than 90%of the Staphylococci at concentrations of 1 jwg/ml or less (Fig. 5) . The in vitro activity of potassium mersacidin which has been tested against a limited number of strains is shown in Table 1 . Its activity is comparable to that of mersacidin. The in vivo activity of mersacidin, against both the methicillin-sensitive S. aureus SG 511 and the methicillin-resistant strains, S. aureus E 710 and S. aureus C 31155 is superior to that of vancomycin ( Table 2 ). The ED50 and ED90 values are both lower. Against S. pyogenes A 77 mersacidin is less active than vancomyicin (Table 3 ). This deficiency has been overcome by the water soluble derivative, potassium mersacidin, with ED50 and ED90 values as good as those obtained with vancomycin ( activity of this derivative against S. aureus (both methicillin-sensitive and -resistant strains) remains comparable to that of mersacidin.
Discussion
Mersacidin is a new memberof the group called lantibiotics, and has some interesting properties not hitherto reported for any other member of this group. It is a narrow spectrum antibiotic active only against Gram-positive bacteria. Its in vitro activity is poor as compared to clinically useful antibiotics like vancomycinand erythromycin. However, in the in vivo system the picture is totally reversed where mersacidin shows an overall better profile than vancomycin. Only against Streptococcus is mersacidin less active than vancomycin in the animal system. This disadvantage has been overcome by making the water soluble derivative, potassium mersacidin. And it is interesting to note that this improvement has taken place not at the cost of its activity against Staphylococcus, where the activity against both methicillinsensitive and methicillin-resistant strains remains almost the sameas with mersacidin. The phenomenon of an antibiotic of having significantly higher in vivo activity than would be predicted from in vitro activity is rare. Recently, a similar phenomenon was reported with spiramycin7) which has 2 to 4 times poorer in vitro activity than erythromycin, whereas the ED50in the septicemia model is 5 to 15 times superior. It has been explained that this paradox can be, at least partly, due to the ability of spiramycin to achieve intracellular and tissue concentrations that exceed serum concentrations by a factor of 10 or more. In case of mersacidin the mechanismby which it shows higher activity in the in vivo system is not yetknown.
